A 3-year-old boy is brought to the pediatric clinic with severe global developmental delay. On examination, he has coarse facial features, hepatosplenomegaly, and a heart murmur. Biochemical investigations reveal elevated urinary glycosaminoglycans. Genetic testing confirms mucopolysaccharidosis type I (MPS I). What is the drug of choice for disease-modifying therapy in this child?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.